ImpediMed Launches $15.2M Raise to Scale FDA-Cleared Lymphoedema Platform
ImpediMed launches $15.2 million capital raise to accelerate SOZO platform growth
ImpediMed Limited has received firm commitments for a $13.2 million placement alongside a $2.0 million Share Purchase Plan (SPP), raising a total of $15.2 million at $0.010 per share. The placement attracted strong support from new and existing institutional investors, with Directors committing $0.6 million in aggregate. 1,320 million new shares will be issued under the placement, strengthening the balance sheet and funding commercial execution in the US market — the company’s key growth region.
When big ASX news breaks, our subscribers know first
How bioimpedance spectroscopy powers early lymphoedema detection
Bioimpedance spectroscopy (BIS) is a non-invasive diagnostic technology that measures fluid changes in the body by passing a low-level electrical current through tissue. The SOZO platform uses this technology to detect early signs of lymphoedema — a chronic condition involving fluid buildup that commonly affects cancer patients following treatment. ImpediMed’s SOZO is the only FDA-cleared BIS technology for lymphoedema assessment, positioning the company as the sole provider of guideline-recommended objective screening.
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines In Oncology for Survivorship reference BIS as the recommended screening tool for at-risk cancer patients. This clinical endorsement creates a defensible market position, supporting the expansion of payor coverage to 328 million US covered lives (representing 94.3% national coverage) as reported in the company’s Q3 FY26 update.
Capital raise structure and key terms
Placement details across two tranches
The placement is structured across two tranches totalling $13.2 million. Tranche 1 will raise $3.0 million through the issue of 300 million shares using existing ASX Listing Rule 7.1 capacity, settling 7 May 2026. Tranche 2 will raise $10.2 million through the issue of 1,020 million shares, subject to shareholder approval at an Extraordinary General Meeting (EGM) in June, with settlement expected approximately 12 June 2026.
| Tranche | Amount Raised | Shares Issued | Settlement Date | Approval Required |
|---|---|---|---|---|
| Tranche 1 | $3.0 million | 300 million | 7 May 2026 | Existing capacity |
| Tranche 2 | $10.2 million | 1,020 million | ~12 June 2026 | EGM approval |
The placement price represents a 28.6% discount to the last closing price of $0.014 on 29 April 2026 (the last trading day before the announcement) and a 28.8% discount to the 15-day volume-weighted average price.
Free attaching options sweeten the deal
Each placement participant will receive one free Attaching Option per share subscribed (exercisable at $0.010 each, expiring 31 March 2027) plus one Follow-on Option (exercisable at $0.015 per option, expiring 31 December 2027) that may be exercised following the valid exercise of an Attaching Option. All Options are intended to be quoted on ASX, subject to meeting ASX requirements and shareholder approval at the EGM.
The option structure provides a pathway to additional funding of up to $32.7 million if all options are exercised (1,320 million Attaching Options at $0.010 = $13.2 million, plus 1,320 million Follow-on Options at $0.015 = $19.8 million). This creates potential for further balance sheet strengthening without requiring an additional capital raise.
Share Purchase Plan offers retail shareholders equal access
Eligible shareholders whose registered address is in Australia or New Zealand and who held shares as at 7:00pm AEST 1 May 2026 can apply for up to $100,000 of shares without incurring brokerage or transaction costs. The SPP price will be the lower of $0.010 or a 2.5% discount to the 5-day VWAP at the closing date of the SPP, rounded to the nearest 0.1 cent.
The SPP aims to raise $2.0 million through the issue of up to 200 million shares. ImpediMed reserves the right to accept oversubscriptions of up to an additional 100 million shares (approximately $1.0 million) at its discretion. Applications may be subject to scale back at the company’s absolute discretion.
Key dates for the SPP:
- SPP opens: 12 May 2026
- SPP closes: 5:00pm AEST 5 June 2026
- SPP results announced: 10 June 2026
- EGM: 11:00am AEST 11 June 2026
- New shares commence trading: Before 12:00pm AEST 15 June 2026
An institutional fund has committed to subscribe for up to $1.8 million of shares if the SPP is undersubscribed, subject to shareholder approval. The SPP shortfall investor would receive shares at the same issue price as other SPP participants. Consistently with the placement, SPP participants will receive one Attaching Option and one Follow-on Option for every share subscribed, subject to shareholder approval at the EGM.
Use of proceeds and debt facility amendments
Proceeds from the capital raise will be used to partially prepay the SWK Growth Capital Facility, strengthening the balance sheet, and to provide additional working capital for ongoing operations and commercial strategy execution as the company scales commercial adoption of the SOZO platform in the US market.
ImpediMed has negotiated amendments to the SWK Growth Capital Facility. SWK has agreed to permit partial prepayments of the facility, reduce minimum total revenue covenant levels applicable to each fiscal quarter from 30 June 2026 onward, and waive testing of certain revenue covenants related to the fiscal quarter ending 31 March 2026. These amendments are conditional on ImpediMed completing a capital raise of at least $10 million (net of costs) on or prior to 30 June 2026 and implementing cost reduction measures of at least $5.0 million from 1 July 2026.
The covenant amendments provide operational flexibility during the growth phase. By reducing minimum revenue thresholds and waiving Q3 FY26 covenant testing, SWK has acknowledged the company’s transition period while maintaining accountability through the capital raise and cost reduction conditions.
$5.0 million cost reduction programme targets FY28 cash flow breakeven
ImpediMed will implement operational initiatives delivering at least $5.0 million in annualised operating cost reductions, effective 1 July 2026. The combination of the capital raise and cost reduction programme provides a pathway to operating cash flow breakeven in FY28, assuming full exercise of the Options prior to maturity.
The cost reductions are a pre-condition for the SWK facility amendments and represent a structural shift in the company’s operating model. By removing $5.0 million in annualised costs whilst maintaining commercial momentum in the US market, management is targeting a leaner, more sustainable operating base. The FY28 breakeven target is contingent on option holders exercising both the Attaching Options and Follow-on Options, which would inject the full $32.7 million in additional capital.
Management commentary signals execution focus
Erik Anderson, Managing Director and CEO
“This capital raise strengthens the Company’s balance sheet and provides the funding required to execute our near‑term priorities. With this support, the management team is focused on disciplined execution, accelerating revenue growth and building a more sustainable and scalable business.”
Chair of the Board Christine Emmanuel-Donnelly acknowledged the ongoing support from long-term shareholders and welcomed new investors who supported the raise. She emphasised the Board’s conviction that SOZO technology has the potential to become the standard of care in breast cancer-related lymphoedema (BCRL), alongside confidence in expanding into the Heart Health and Weight Management categories. Under Erik Anderson’s leadership, the Board looks forward to executing the long-term commercialisation strategy and the restoration of shareholder value.
The next major ASX story will hit our subscribers first
Recent operational momentum underpins raise timing
The capital raise follows the company’s Q3 FY26 Quarterly Activity and Cash Flow Report lodged with ASX on 30 April 2026, which highlighted:
- Annual Recurring Revenue: $14.1 million ($14.9 million constant currency)
- SOZO Core Business TCV: $5.4 million
- BCRL reimbursement coverage: 328 million US covered lives (94.3% national coverage)
- Heart Health and Weight Management activities commenced in the US, including initial sales
- Appointment of new Managing Director / CEO Erik Anderson
The raise timing follows demonstrated commercial traction rather than speculative development-stage promises. With Annual Recurring Revenue approaching $15 million and near-total US payor coverage for BCRL indications, the company has shifted from proving market access to scaling commercial execution. The commencement of Heart Health and Weight Management sales represents early validation of platform diversification beyond the core lymphoedema indication, potentially expanding the addressable market significantly.
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts the moment market-moving healthcare and biotech announcements break.